Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Pickart, J
Phase 3 Trial Completion (2026) Before Eli Lilly can ask for approval, it needs to finish its main trials
specifically examined patients with MASLD cirrhosis and type 2 diabetes, finding that GLP-1 receptor agonist initiation was linked to reduced risk of unfavorable liver outcomes including hepatic decompensation events and mortality from any cause (aHR: 0.78, 95%CI: 0.68-0.90) relative to non-users, suggesting potential benefits even in advanced liver disease populations [58]
Published: Jul 23, 2025 Written by Bianca Deng Medically Reviewed by Klarity Editorial Team Published: Jul 23, 2025 Key takeaway: Getting a GLP-1 prescription is now easier than ever through telehealth
Winter SC: Treatment of carnitine deficiency
US$ 25.49
US$ 24.17
US$ 21.27
US$ 26.66
US$ 25.03
